- Home
- MSB vs ZVRA Comparison
MSB vs ZVRA Comparison
Compare MSB & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MSB | ZVRA |
|---|---|---|
| Founded | 1961 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.0M | 472.9M |
| IPO Year | 1995 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MSB | ZVRA |
|---|---|---|
| Price | $31.40 | $8.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.71 |
| AVG Volume (30 Days) | 35.9K | ★ 553.2K |
| Earning Date | 04-17-2026 | 01-01-0001 |
| Dividend Yield | ★ 4.27% | N/A |
| EPS Growth | ★ 391.29 | 34.27 |
| EPS | 0.85 | ★ 1.16 |
| Revenue | ★ $98,595,651.00 | $23,612,000.00 |
| Revenue This Year | N/A | $333.64 |
| Revenue Next Year | N/A | $44.19 |
| P/E Ratio | $35.38 | ★ $7.73 |
| Revenue Growth | ★ 331.26 | N/A |
| 52 Week Low | $22.55 | $6.19 |
| 52 Week High | $42.38 | $13.16 |
Technical Indicators
Market Signals| Indicator | MSB | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 43.35 | 55.64 |
| Support Level | $28.88 | $8.61 |
| Resistance Level | $32.64 | $9.10 |
| Average True Range (ATR) | 1.79 | 0.36 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 60.41 | 79.27 |
Price Performance
Historical ComparisonAbout MSB Mesabi Trust
Mesabi Trust operates as a royalty trust in the United States. The company is involved in the conservation and protection of its assets. The company's principally wholly-owned segment is the iron ore mining segment, which generates income from the Peter Mitchell Mine, an iron mine located near Babbitt, Minnesota, at the eastern end of the Mesabi Iron Range.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.